This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 code | I42.28 |
|---|---|
| Special Copayment Reduction code | V289 |
| Synonyms / related terms | Nonobstructive hypertrophic cardiomyopathy, asymmetric hypertrophic cardiomyopathy, apical hypertrophic cardiomyopathy, familial hypertrophic cardiomyopathy |
| Classification | Severe intractable disease (Special Copayment Reduction registration criteria: 5 years) |
Hypertrophic cardiomyopathy (HCM) was first described in 1958 by Teare, who found asymmetric left ventricular hypertrophy and myofibrillar disarray in adolescents who died suddenly. In 1960, Braunwald systematized the clinical-hemodynamic characteristics including outflow tract obstruction and distinguished obstructive HCM (HOCM) from nonobstructive HCM.
I42.28 (other hypertrophic cardiomyopathy) includes hypertrophic cardiomyopathy without left ventricular outflow tract obstruction (LVOTO) or with an atypical hypertrophy pattern, or other forms not classified as I42.1 (obstructive hypertrophic cardiomyopathy). Since the discovery of MYH7 (beta-myosin heavy chain) variants as the first HCM-causing gene in 1989, advances in molecular genetics have shown that more than 60 genes are now associated with HCM.
In the 2020 AHA/ACC guideline and the 2023 ESC guideline, the system for diagnosis, risk assessment, and treatment of HCM was comprehensively updated, and in particular the clinical introduction of cardiac myosin inhibitors such as mavacamten opened a new era of drug treatment for HCM.
The main cause of HCM is mutation of genes encoding cardiac sarcomere proteins. Sarcomere gene variants are identified in about 40-60% of all HCM, and the rest is idiopathic with no gene variant found.
The most common causative genes are MYH7 (beta-myosin heavy chain; about 30-40% of the total) and MYBPC3 (cardiac myosin-binding protein C; about 30-40% of the total). Among MYBPC3 variants, loss-of-function (truncating) variants are the most common, with late onset and incomplete penetrance.
Other HCM-related genes: TNNI3 (cardiac troponin I), TNNT2 (cardiac troponin T), TPM1 (tropomyosin 1), MYL2 (regulatory light chain), MYL3 (essential light chain), ACTC1 (cardiac alpha-actin), CSRP3 (muscle LIM protein). Phenocopy diseases that mimic HCM must be differentiated: Fabry disease (GLA variants), glycogen storage disease type III (GAA)/type IX (PHKA1), amyloidosis (ATTR, AL), Noonan syndrome (PTPN11, SOS1), dantrolene storage cardiomyopathy, Friedreich ataxia (FRDA), and so on.
Autosomal dominant inheritance is the main mode of inheritance of HCM, and penetrance varies from 50% to 100% depending on the gene variant. Because of incomplete penetrance and variable expressivity, MYBPC3 variants show diverse clinical phenotypes even within the same family. Patients with double heterozygous mutations or compound heterozygous mutations show a more severe phenotype.
MYBPC3 c.2373insG is a founder mutation found at high frequency in Asian populations, especially South Indians. In Korean HCM patients as well, MYH7 and MYBPC3 variants are the most frequent, and a gene spectrum similar to that of Europeans has been reported.
Genetic testing (cardiomyopathy gene panel or WES): performed under a specialist's judgment after the HCM diagnosis is confirmed, and when the result is positive, first-degree relative screening and genetic counseling are recommended. Interpretation of variants of uncertain significance (VUS) causes difficulty in clinical management decisions, so interpretation by a geneticist or a cardiac geneticist with relevant experience is important.
HCM is the most common inherited cardiomyopathy, with a worldwide prevalence of about 1/200-1/500 (0.2-0.5% of the adult population). Accurate domestic prevalence statistics are limited, but an echocardiography-based epidemiological study estimated it at about 0.2% of the adult population.
I42.28 (other hypertrophic cardiomyopathy) includes nonobstructive HCM without LVOTO, or cases with an atypical hypertrophy pattern (apical, posterior, etc.), and about 70% of all HCM is nonobstructive without resting obstruction or has labile obstruction. Apical HCM is relatively common in East Asians and accounts for about 15-20% of HCM patients in Korea.
HCM is known as the most common cause of sudden death in athletes aged 35 or younger. The annual mortality is about 0.5-1%, and with appropriate management some patients have a life expectancy similar to the general population. Patients registered under the domestic Special Copayment Reduction (V289) benefit from a 10% copayment on treatment costs.
The core pathophysiology of HCM is cardiomyocyte hypercontractility and diastolic dysfunction due to abnormal sarcomere protein function. Abnormal actomyosin cross-bridging caused by MYH7 and MYBPC3 variants leads to reduced myocardial energy efficiency and increased cardiomyocyte ATP consumption.
The resulting persistent sarcomere hypercontractility causes cardiomyocyte hypertrophy, myofibrillar disarray, and interstitial fibrosis, which become the substrate for diastolic dysfunction, microvascular ischemia, and ventricular arrhythmia. Calcium handling abnormalities (increased Ca2+ sensitivity, abnormal SR Ca2+ release) also contribute to sarcomere hyperactivation.
Elevated left ventricular filling pressure due to diastolic dysfunction is the main mechanism of exercise intolerance and dyspnea. Myocardial ischemia from microvascular dysfunction contributes to chest pain, myocardial fibrosis, and formation of the arrhythmia substrate. The extent of myocardial fibrosis (LGE on CMR) is associated with ventricular arrhythmia risk and poor prognosis.
The clinical symptoms of HCM range from asymptomatic to severe. The most common symptom is exertional dyspnea, mainly caused by pulmonary congestion from diastolic dysfunction. In obstructive HCM (LVOTO), symptoms worsen with the Valsalva maneuver and on standing.
Chest pain (angina-like chest pain): caused by microvascular dysfunction and myocardial ischemia, worsening during exercise and relieved at rest. Dizziness, presyncope, and syncope: syncope occurring during exercise suggests hemodynamic compromise due to ventricular arrhythmia or LVOTO and may be a precursor of sudden death.
Palpitation: caused by atrial fibrillation (occurring in about 20-30% of HCM patients) and nonsustained ventricular tachycardia. In apical HCM, characteristic ECG findings of cardiac deformity (giant T-wave inversion, ST depression in V4-V6, deep Q waves) may be observed, and patients are often asymptomatic early on.
Examination findings in obstructive HCM (HOCM): jerky pulse, double apical impulse, harsh crescendo-decrescendo systolic murmur (left sternal border and apex, increased with Valsalva, decreased on squatting), and S4 gallop are characteristic.
In nonobstructive HCM (I42.28), the murmur may be absent or faint, making clinical diagnosis difficult. A forceful, left-displaced apical impulse due to cardiac hypertrophy may be observed. An irregular pulse is found when atrial fibrillation occurs.
CMR LGE findings: LGE is observed in areas of myocardial fibrosis, and a fibrosis extent of 5% or more is associated with ventricular arrhythmia and sudden death risk. Microvascular obstruction and a nonischemic-distribution LGE pattern are characteristic of HCM.
Electrocardiogram (ECG): about 90% of HCM patients have an abnormal ECG. Characteristic findings include left ventricular hypertrophy (Cornell criteria, Sokolow-Lyon criteria), deep Q waves (especially in inferior-lateral leads), giant negative T waves (V4-V6 in apical HCM; Negative T>1mV), left axis deviation, and left atrial enlargement.
24-hour Holter ECG: checking for nonsustained ventricular tachycardia (NSVT) is included in sudden death risk assessment. The presence of NSVT is regarded as a sudden death risk factor. Echocardiography: ventricular wall thickness (maximum LV wall thickness ≥ 15mm; ≥ 13mm in first-degree relatives), LVOTO pressure gradient, SAM (systolic anterior motion), and diastolic function indices (E/e', TR velocity) are assessed.
Exercise stress test (treadmill or bicycle ergometer): used for blood pressure response (a fall in blood pressure during exercise is a sudden death risk factor), provocation of symptoms, and dynamic assessment of obstruction. For first-degree relatives of family members with confirmed HCM, echocardiography and ECG screening every 3-5 years is recommended for adults.
HCM diagnostic criteria: asymmetric left ventricular hypertrophy not explained by other causes (systemic or metabolic causes, cardiac loading conditions), maximum ventricular wall thickness ≥ 15mm (adult criterion; ≥ 13mm in first-degree relatives or if gene-positive). 2D echocardiography is the first-line diagnostic test.
Cardiac MRI (CMR): used to evaluate apical, posterior, and anterolateral hypertrophy areas not adequately assessed on echocardiography, for precise measurement of ventricular wall thickness, and for quantifying the extent of LGE-based myocardial fibrosis. Sudden death risk assessment (ESC 2022 HCM Risk-SCD score): a score model including age, maximum LV thickness, left atrial size, LVOTO pressure gradient, nonsustained ventricular tachycardia, history of syncope, and family history of sudden death predicts the 5-year sudden death risk.
Exclusion of HCM phenocopies: Fabry disease (males; alpha-galactosidase A activity, GLA variants), ATTR amyloidosis (bone scan, TTR gene testing), LEOPARD syndrome, mitochondrial cardiomyopathy (serum lactate, muscle biopsy), and so on are differentiated. For Special Copayment Reduction (V289) registration, submit a cardiology specialist diagnosis certificate, echocardiography results, and CMR results if needed.
Asymptomatic nonobstructive HCM can be followed without specific drug treatment, but participation in high-intensity exercise (competitive sports) is restricted. Symptoms due to diastolic dysfunction (dyspnea) are controlled with beta-blockers (metoprolol, bisoprolol) and non-dihydropyridine calcium channel blockers (verapamil, diltiazem).
Mavacamten (cardiac myosin ATPase inhibitor): a new-mechanism HCM drug approved by the FDA in 2022; the EXPLORER-HCM study confirmed reduced LVOTO pressure gradient and functional improvement in symptomatic obstructive HCM. The ODYSSEY-HCM study is ongoing in nonobstructive HCM. It is contraindicated at an ejection fraction < 50%, and echocardiographic monitoring every 3 months is required.
ICD: considered in HCM sudden death risk assessment when the 5-year risk is ≥ 6% (ESC model) or there is at least one major risk factor (AHA/ACC model; nonsustained ventricular tachycardia, maximum LV thickness ≥ 30mm, abnormal blood pressure response to exercise, syncope, family history of sudden death). Atrial fibrillation management: rhythm control (amiodarone, sotalol) and anticoagulation (warfarin or NOAC) are needed to prevent thromboembolism.
The prognosis of HCM varies with the type of gene variant, clinical phenotype, and number of sudden death risk factors. Overall annual mortality is about 0.5-1%, and many patients can have a life expectancy similar to the general population with ICD implantation and optimal drug therapy.
Poor prognostic factors: maximum LV wall thickness ≥ 30mm, myocardial LGE extent ≥ 15% of LV mass, nonsustained ventricular tachycardia, history of syncope due to ventricular arrhythmia, family history of sudden death, severe LVOTO, and atrial fibrillation. In nonobstructive HCM (I42.28) as well, comorbid atrial fibrillation increases the risk of thromboembolism (stroke), and this must be managed regardless of the presence of LVOTO.
HCM with MYBPC3 variants has a relatively favorable prognosis compared with MYH7 variants. Apical HCM carries an increased risk of apical thrombus, apical aneurysm, and stroke, and in the long-term course some may convert to a DCM pattern ("end-stage HCM"). Regular follow-up (at 1-2 year intervals) with risk reassessment is needed.
Primary prevention of hereditary HCM is not possible. Early diagnosis through family screening is the key to preventing secondary complications (sudden death, heart failure). First-degree relatives (parents, siblings, children) of patients with confirmed HCM should undergo echocardiography and ECG screening every 3-5 years in adulthood, and more frequently in adolescence considering the possibility of hypertrophy emerging with growth.
Secondary prevention of sudden death with an ICD: ICD implantation is recommended in survivors of ventricular arrhythmia or in patients with a 5-year sudden death risk ≥ 6%. Participation in vigorous exercise (competitive sports) is restricted in the high-risk group, but low- to moderate-intensity aerobic exercise (walking, swimming, cycling) is permitted in most HCM patients.
Dehydration prevention: caution is needed because excessive diuretic use, prolonged exposure to hot environments, and excessive alcohol intake can reduce blood volume and worsen LVOTO. In HCM-like diseases such as amyloidosis and Fabry disease, disease-specific treatment of the underlying disease (tafamidis/agalsidase, etiologic treatment) is important for suppressing disease progression. At the 5-year Special Copayment Reduction renewal, specialist confirmation including the latest echocardiography, CMR LGE results, and risk reassessment results is required.